Search results
...I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer - Puma Biotechnology (NASDAQ:PBYI)
Benzinga· 2 days agoPuma Biotechnology, Inc. PBYI, a biopharmaceutical company, announced the presentation of alisertib for the treatment of patients with advanced osimertinib-resistant epidermal growth factor ...
National Cancer Survivors Day is a celebration of life
Rolling Out· 2 days agoJune 2 marks a significant occasion for many individuals and families across the globe—it's National...
Cancer Patients Get Poorer Care at Hospitals Serving Minority Communities
KTBS Shreveport· 6 days agoCancer patients receive poorer care at hospitals that mainly serve minority communities. THURSDAY,...
Study: Access to Targeted Lung Cancer Drug Is Cost | Newswise
Newswise· 6 days ago“Cost-effectiveness analyses can help establish a value-based price for discussions with payers,”...
ASCO24: Tagrisso in the spotlight, Caribou’s adjustment and Lilly’s KRAS competitor
BioPharma Dive via Yahoo Finance· 2 days agoA larger Phase 3 trial is now enrolling. — Ned Pagliarulo Over the past several years, drugmakers...
Owner and restaurateur of Vincent's Italian Cuisine dies
WWL-TV, Channel 4 New Orleans· 5 days agoVincent Catalanotto Sr. was 70 years old. He died of lung cancer at Ochsner Health Center-Kenner.
Tumor infiltrating lymphocyte approval heralds new era for precision cancer immunotherapy
Nature· 6 days agoFDA approval of Iovance’s lifileucel for melanoma shows the promise of tumor-infiltrating lymphocytes for the treatment of solid tumors, with trials ongoing for lung
Wealthy people ‘at greater risk of cancer’ than the rest of us: study
NY Post via Yahoo News· 3 days agoStudy leader Dr Fiona Hagenbeek, of the university’s Institute...context-dependent may lead to...
Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib(ROS1 Inhibitor) are...
ThePress.net· 4 days agoData were reported from 173 patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) who were treated with taletrectinib.
...Ifebemtinib in Combination with Garsorasib in Non-Small Cell Lung Cancer (NSCLC) with KRAS G12C...
WKBN 27 Youngstown· 6 days ago...May 30, 2024 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company developing innovative therapies against tumor-treatment resistance and metastasis, today announced results from the Phase Ib/II clinical trial of ifebemtinib, the company's focal adhesion kinase (FAK) inhibitor,...